SecBot SecBot
SECBOTREPLAY Home › Report › FHTX

FHTX · Foghorn Therapeutics presented new preclinical data at AACR 2026…

Foghorn Therapeutics Inc. · 8-K filed Apr 21, 2026 at 16:01 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 21, 2026 at 16:01 ET

Foghorn Therapeutics presented new preclinical data at AACR 2026 showing promising results across its pipeline, including complete tumor regression with FHD-909 in combination with anti-PD1 and strong efficacy in multiple degrader programs. The company also announced its ongoing collaboration with Lilly.

  • FHD-909 in combination with anti-PD1 demonstrated complete and durable tumor regression in preclinical models
  • Selective CBP degrader FHT-171 showed strong anti-tumor activity in ER+ breast cancer models
  • Selective EP300 degrader outperformed clinical benchmark in multiple myeloma models
  • Robust degradation achieved with cereblon-based selective ARID1B degraders

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access